Is Having Inflammatory Bowel Disease a Risk Factor for
Severe Acute Respiratory Syndrome Coronavirus 2?

Background: The severe acute respiratory syndrome coronavirus 2 virus was found to have effects not only in the lungs but also in many different organs. We aimed to evaluate the management of our patients with inflammatory bowel disease in this pandemic, the incidence of coronavirus disease 2019 in terms of clinical, medical treatment, and features of inflammatory bowel disease, and to investigate the effects of the severe acute respiratory syndrome coronavirus 2 on this particular group of patients. Methods: During the coronavirus disease 2019 pandemic, 207 patients who had inflammatory bowel disease for at least 6 months were questioned for coronavirus disease 2019 at their outpatient clinic admissions, and their medical records were evaluated prospectively. Results: Of the 207 patients, 146 had Crohn’s disease. The mean disease duration was determined as 118.15 ± 72.85 months. Of the patients, 127 (61.4%) were using mesalazine, 110 (53.1%) azathioprine, and 148 (71.5%) biological agents. It was found that 66 (31.9%) patients changed their medications during the coronavirus disease 2019 pandemic. As a medication change, anti-Tumor Necrosis Factor (TNF) dose was observed to be omitted most frequently at a rate of 80%. Diarrhea was present in 20.8%, abdominal pain in 20.3%, nausea in 10.6%, anorexia in 13.5%, and weight loss in 15.9% of the patients. Twelve (5.79%) patients were diagnosed with coronavirus disease 2019. Lung involvement was present in 11 (91.7%) of the patients diagnosed with coronavirus disease 2019. Of the patients diagnosed and not diagnosed with coronavirus disease 2019, 75% vs. 71.6% were using biological agents (P = .80), respectively. Half of the patients diagnosed with coronavirus disease 2019 were active in terms of inflammatory bowel disease at the time of diagnosis, and 2 of these patients were severely active. Conclusion: The incidence of coronavirus disease 2019 infection in patients with inflammatory bowel disease was not different from the general population during the severe acute respiratory syndrome coronavirus 2 pandemic. Coronavirus disease 2019 infection does not progress with poor prognosis in patients with inflammatory bowel disease who receive immunosuppressive therapy including biological agents.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. World Health Organization (WHO). WHO Director-General’s opening remarks at the media briefing on COVID-19. 2020. Available at: https://www.who.int/dg/speeches/detail/who-directorgeneral-sopening-remarks-at-the-media-briefing-on-covid19-11-march-2020, Accessed March 11, 2020.
2. Centres for Disease Control and Prevention (CDC). Coronavirus Disease 2019 (COVID-19): Cleaning and Disinfection for Community Facilities. 2020. https://www.cdc.gov/coronavirus/2019-ncov/ community/disinfecting-building-facility.html.
3. Coperchini F, Chiovato L, Croce L, Magri F, Rotondi M. The cytokine storm in COVID-19: an overview of the involvement of the chemokine/ chemokine-receptor system .Cytokine Growth Factor Rev. 2020;53:25-32. [CrossRef]
4. Monteleone G, Are SA. Are patients with inflammatory bowel disease at increased risk for Covid-19 infection? J Crohns Colitis. 2020;14(9):1334-1336. [CrossRef]
5. Shang J, Wan Y, Luo C, et al. Cell entry mechanisms of SARSCoV-2. PNAS. 2020;117(21):11727-11734. [CrossRef]
6. de Mattos BRR, Garcia MPG, Nogueira JB. Inflammatory bowel disease: an overview of immune mechanisms and biological treatments mediators of inflammation. Mediators Inflamm. 2015;2015:493012. [CrossRef]
7. Danese S, Sands B, Ng SC, Peyrin-Biroulet L. The day after COVID19 in IBD: how to go back to ‘normal’. Nat Rev Gastroenterol Hepatol. 2020;17(8):441-443. [CrossRef]
8. Ling KL, Hilmi I, Ali RAR, et al. Asian Pacific Association of Gastroenterology (APAGE) Inflammatory Bowel Disease (IBD) Working Party guidelines on IBD management during the COVID‐19 pandemic. JGH Open. 2020;4(3):320-323. [CrossRef]
9. Bezzio C, Saibeni S, Variola A, et al. Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study. Gut. 2020;69(7):1213- 1217. [CrossRef]
10. Caron B, Arondel Y, Reimund J-M. Covid-19 and inflammatory bowel disease: questions on incidence, severity, and impact of treatment? Clin Gastroenterol Hepatol. 2020;18(11):2637-2638. [CrossRef]
11. Khan N, Patel D, Xie D, et al. Impact of anti-TNF and thiopurines medications on the development of COVID-19 in patients with inflammatory bowel disease: a nationwide veterans administration cohort study. Gastroenterology. 2020;159(4):1545-1546.e1. [CrossRef]
12. Popa IV, Diculescu M, Mihai C, Cijevschi-Prelipcean C, Burlacu A. COVID-19 and inflammatory bowel diseases: risk assessment, shared molecular pathways, and therapeutic challenges. Gastroenterol Res Pract. 2020;2020:1918035. [CrossRef].
13. Brenner EJ, Ungaro RC, Gearry RB, et al. Corticosteroids, but not TNF antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: results from an international registry. Gastroenterology. 2020;159(2):481-491.e3. [CrossRef]
14. Jiang F, Deng L, Zhang L, Cai Y, Cheung CW, Xia Z. Review of the clinical characteristics of coronavirus disease 2019 (COVID-19). J Gen Intern Med. 2020;35(5):1545-1549. [CrossRef]
15. Ma C,Gu J, Hou P, et al. Incidence, clinical characteristics and prognostic factor of patients with COVID-19: a systematic review and meta-analysis. medRxiv. [CrossRef]
16. Rubin DT, Abreu MT, Rai V, Siegel CA, International Organization for the Study of Inflammatory Bowel Disease. Management of patients with Crohn’s disease and ulcerative colitis during the coronavirus disease-2019 pandemic: results of an international meeting. Gastroenterology. 2020;159(1):6-13.e6. [CrossRef]
17. de León-Rendón JL, Hurtado-Salazar C, Yamamoto-Furusho JK. Aspects of inflammatory bowel disease during the COVID-19 pandemic and general considerations. Rev Gastroenterol Mex (Engl Ed). 2020;85(3):295-302. English, Spanish. [CrossRef]. Epub 2020 May 23. PMID: 32536480; PMCID: PMC7245301.
18. Ning L, Shan G, Sun Z, et al. Quantitative proteomic analysis reveals the deregulation of nicotinamide adenine dinucleotide metabolism and CD38 in inflammatory bowel disease. BioMedres Int. 2019;2019:21.
19. Norsa L, Indriolo A, Sansotta N, et al. Uneventful course in IBD patients during SARS-CoV-2 outbreak in Northern Italy. Gastroenterology. 2020;159(1):371-372. [CrossRef]
20. Tursi A, Vetrone LM, Papa A. Anti-TNF-α agents in inflammatory bowel disease and course of COVID-19. Inflamm Bowel Dis. 2020;26(7):e73. [CrossRef]
21. Doering J, Begue B, Lentze MJ, et al. Induction of T lymphocyte apoptosis by sulphasalazine in patients with Crohn’s disease. Gut. 2004;53(11):1632-1638. [CrossRef]
22. Fredi M, Cavazzana I, Moschetti L, Andreoli L, Franceschini F, on behalf of the Brescia Rheumatology COVID-19 Study Group. COVID19 in patients with rheumatic diseases in northern Italy: a singlecentre observational and case–control study. Lancet Rheumatol. 2020;2(9):E549-E556. [CrossRef]
23. Gianfrancesco M, Hyrich KL, Al-Adely S, et al. Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 global rheumatology alliance physician-reported registry. Ann Rheum Dis. 2020;79(7):859- 866. [CrossRef]
24. Rubin DT, Feuerstein JD, Wang AY, Cohen RD. AGA clinical practice update on management of inflammatory bowel disease during the COVID-19 pandemic: expert commentary. Gastroenterology. 2020;159(1):350-357. [CrossRef]
25. D’Amico F, Baumgart DC, Danese S, Peyrin-Biroulet L. Diarrhea during COVID-19 infection: pathogenesis, epidemiology, prevention, and management. Clin Gastroenterol Hepatol. 2020;18(8):1663- 1672. [CrossRef]
26. Song Y, Liu P, Shi XL, et al. SARS-CoV-2 induced diarrhoea as onset symptom in patient with COVID-19. Gut. 2020;69(6):1143- 1144. [CrossRef]
27. Kennedy NA, Jones G-R, Lamb CA, et al. British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic. Gut. 2020;69(6):984-990. [CrossRef]

APA	Çavuş B, Akyuz F, Ormeci A, Ozgur I, EREL GEZEGEN C, YAKUT A, Imanov Z, Senkal I, Medetalibeyoglu A, Kose M, Keskin M, Demir K, Beşışık F, Kaymakoglu S (2022). Is Having Inflammatory Bowel Disease a Risk Factor for Severe Acute Respiratory Syndrome Coronavirus 2?. , 196 - 204. 10.5152/tjg.2022.211113
Chicago	Çavuş Bilger,Akyuz Filiz,Ormeci Asli,Ozgur Ilker,EREL GEZEGEN CANSU,YAKUT AYSUN,Imanov Ziya,Senkal Ibrahim volkan,Medetalibeyoglu Alpay,Kose Murat,Keskin Metin,Demir Kadir,Beşışık Fatih,Kaymakoglu Sabahattin Is Having Inflammatory Bowel Disease a Risk Factor for Severe Acute Respiratory Syndrome Coronavirus 2?. (2022): 196 - 204. 10.5152/tjg.2022.211113
MLA	Çavuş Bilger,Akyuz Filiz,Ormeci Asli,Ozgur Ilker,EREL GEZEGEN CANSU,YAKUT AYSUN,Imanov Ziya,Senkal Ibrahim volkan,Medetalibeyoglu Alpay,Kose Murat,Keskin Metin,Demir Kadir,Beşışık Fatih,Kaymakoglu Sabahattin Is Having Inflammatory Bowel Disease a Risk Factor for Severe Acute Respiratory Syndrome Coronavirus 2?. , 2022, ss.196 - 204. 10.5152/tjg.2022.211113
AMA	Çavuş B,Akyuz F,Ormeci A,Ozgur I,EREL GEZEGEN C,YAKUT A,Imanov Z,Senkal I,Medetalibeyoglu A,Kose M,Keskin M,Demir K,Beşışık F,Kaymakoglu S Is Having Inflammatory Bowel Disease a Risk Factor for Severe Acute Respiratory Syndrome Coronavirus 2?. . 2022; 196 - 204. 10.5152/tjg.2022.211113
Vancouver	Çavuş B,Akyuz F,Ormeci A,Ozgur I,EREL GEZEGEN C,YAKUT A,Imanov Z,Senkal I,Medetalibeyoglu A,Kose M,Keskin M,Demir K,Beşışık F,Kaymakoglu S Is Having Inflammatory Bowel Disease a Risk Factor for Severe Acute Respiratory Syndrome Coronavirus 2?. . 2022; 196 - 204. 10.5152/tjg.2022.211113
IEEE	Çavuş B,Akyuz F,Ormeci A,Ozgur I,EREL GEZEGEN C,YAKUT A,Imanov Z,Senkal I,Medetalibeyoglu A,Kose M,Keskin M,Demir K,Beşışık F,Kaymakoglu S "Is Having Inflammatory Bowel Disease a Risk Factor for Severe Acute Respiratory Syndrome Coronavirus 2?." , ss.196 - 204, 2022. 10.5152/tjg.2022.211113
ISNAD	Çavuş, Bilger vd. "Is Having Inflammatory Bowel Disease a Risk Factor for Severe Acute Respiratory Syndrome Coronavirus 2?". (2022), 196-204. https://doi.org/10.5152/tjg.2022.211113

APA	Çavuş B, Akyuz F, Ormeci A, Ozgur I, EREL GEZEGEN C, YAKUT A, Imanov Z, Senkal I, Medetalibeyoglu A, Kose M, Keskin M, Demir K, Beşışık F, Kaymakoglu S (2022). Is Having Inflammatory Bowel Disease a Risk Factor for Severe Acute Respiratory Syndrome Coronavirus 2?. Turkish Journal of Gastroenterology, 33(3), 196 - 204. 10.5152/tjg.2022.211113
Chicago	Çavuş Bilger,Akyuz Filiz,Ormeci Asli,Ozgur Ilker,EREL GEZEGEN CANSU,YAKUT AYSUN,Imanov Ziya,Senkal Ibrahim volkan,Medetalibeyoglu Alpay,Kose Murat,Keskin Metin,Demir Kadir,Beşışık Fatih,Kaymakoglu Sabahattin Is Having Inflammatory Bowel Disease a Risk Factor for Severe Acute Respiratory Syndrome Coronavirus 2?. Turkish Journal of Gastroenterology 33, no.3 (2022): 196 - 204. 10.5152/tjg.2022.211113
MLA	Çavuş Bilger,Akyuz Filiz,Ormeci Asli,Ozgur Ilker,EREL GEZEGEN CANSU,YAKUT AYSUN,Imanov Ziya,Senkal Ibrahim volkan,Medetalibeyoglu Alpay,Kose Murat,Keskin Metin,Demir Kadir,Beşışık Fatih,Kaymakoglu Sabahattin Is Having Inflammatory Bowel Disease a Risk Factor for Severe Acute Respiratory Syndrome Coronavirus 2?. Turkish Journal of Gastroenterology, vol.33, no.3, 2022, ss.196 - 204. 10.5152/tjg.2022.211113
AMA	Çavuş B,Akyuz F,Ormeci A,Ozgur I,EREL GEZEGEN C,YAKUT A,Imanov Z,Senkal I,Medetalibeyoglu A,Kose M,Keskin M,Demir K,Beşışık F,Kaymakoglu S Is Having Inflammatory Bowel Disease a Risk Factor for Severe Acute Respiratory Syndrome Coronavirus 2?. Turkish Journal of Gastroenterology. 2022; 33(3): 196 - 204. 10.5152/tjg.2022.211113
Vancouver	Çavuş B,Akyuz F,Ormeci A,Ozgur I,EREL GEZEGEN C,YAKUT A,Imanov Z,Senkal I,Medetalibeyoglu A,Kose M,Keskin M,Demir K,Beşışık F,Kaymakoglu S Is Having Inflammatory Bowel Disease a Risk Factor for Severe Acute Respiratory Syndrome Coronavirus 2?. Turkish Journal of Gastroenterology. 2022; 33(3): 196 - 204. 10.5152/tjg.2022.211113
IEEE	Çavuş B,Akyuz F,Ormeci A,Ozgur I,EREL GEZEGEN C,YAKUT A,Imanov Z,Senkal I,Medetalibeyoglu A,Kose M,Keskin M,Demir K,Beşışık F,Kaymakoglu S "Is Having Inflammatory Bowel Disease a Risk Factor for Severe Acute Respiratory Syndrome Coronavirus 2?." Turkish Journal of Gastroenterology, 33, ss.196 - 204, 2022. 10.5152/tjg.2022.211113
ISNAD	Çavuş, Bilger vd. "Is Having Inflammatory Bowel Disease a Risk Factor for Severe Acute Respiratory Syndrome Coronavirus 2?". Turkish Journal of Gastroenterology 33/3 (2022), 196-204. https://doi.org/10.5152/tjg.2022.211113